Related Experiment Videos

International collaborative study of the spinal muscular atrophies. Part 1. Analysis of clinical and laboratory data

Insights

Early onset spinal muscular atrophy (SMA) before age 4, especially if motor milestones are missed, indicates a poor prognosis. Diagnostic markers include EMG and neurogenic atrophy on muscle biopsy.

Area of Science:

  • Neurology
  • Genetics
  • Pediatrics

Background:

  • Spinal muscular atrophy (SMA) presents with significant variability in age of onset.
  • Early childhood onset, particularly before 4 years, is common and associated with worse outcomes.

Purpose of the Study:

  • To delineate the clinical and diagnostic features of spinal muscular atrophy.
  • To identify prognostic indicators and reliable diagnostic criteria for SMA.

Main Methods:

  • Analysis of clinical presentation, including age of onset, motor development, and physical examination findings.
  • Evaluation of diagnostic tools such as electromyography (EMG), muscle biopsy (histology and histochemistry), and serum creatine kinase levels.

Main Results:

  • Onset before 4 years, inability to sit without support, proximal muscle weakness, and reduced muscle tone are key features.
  • EMG findings (spontaneous activity, increased motor unit potential) and routine neurogenic atrophy on histology are reliable diagnostic markers.
  • Serum creatine kinase is often normal, and CSF chemistry is consistently normal.

Conclusions:

  • Prognosis is significantly worse for early-onset SMA (before 4 years) and those with delayed motor milestones.
  • Neurogenic atrophy on routine histology and specific EMG findings are crucial for SMA diagnosis.
  • Clinical presentation and diagnostic test results aid in predicting disease severity and guiding management.

Related Concept Videos